NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm

EyePoint, Inc. (NASDAQ: EYPT) reported disappointing topline results from Phase 3 clinical trials (press release dated Aug. 17, 2026). Separately, Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws related to the company’s disclosures on behalf of investors reporting significant losses, which adds overhang for the stock.

Analysis

The core issue is not the litigation headline; it is the collapse in probability-weighted value of the lead program and the knock-on effect on financing terms. In small-cap biotech, a pivotal miss typically resets the asset to near-zero until management proves an alternate path, while the legal probe mainly keeps the stock in an investor-unfriendly overhang state and raises the cost of capital.

The second-order winner is the rest of biotech, especially names with cleaner late-stage visibility and balance sheets, because capital will rotate away from binary ophthalmology exposure. That means XBI/IBB constituents with diversified pipelines can quietly benefit from relative inflows, while other pre-commercial ophthalmology names may see higher discount rates into their own readouts. The real loser is not just EYPT holders; it is anyone relying on a future financing or partnership with stronger terms than today.

The contrarian point is that these events are often more liquidity-driven than litigation-driven. If management has enough runway and can credibly pivot to another asset without an immediate dilutive raise, the downside can become a slower bleed instead of a crash. What would falsify the bearish view is a post-data call that preserves a registrational path, or a financing/partnering outcome that shows the market is willing to underwrite the next leg without punitive dilution.

Key Decisions for Investors

• Short EYPT on any 1-2 day relief bounce; prefer a 1-3 month put spread over outright puts if implied volatility is already elevated. Risk/reward improves if the stock cannot reclaim the pre-news trading range.
• Use XBI as the cleaner hedge: long XBI / short EYPT for 1-2 months to express idiosyncratic trial-failure risk while staying beta-neutral to broader biotech sentiment.
• Do not bottom-fish until management discloses cash runway and the next development path. If runway is under 12 months, expect dilution pressure to be the next catalyst, not a recovery.
• Cover or reduce any EYPT short only if the company credibly re-establishes a registrational path or announces partner support that removes near-term financing risk.